A Multicenter Study of Hippocampal Electrical Stimulation (HS, in Mesial Temporal Lobe Epilepsy (METTLE)

March 28, 2012 updated by: Dr. Sam Wiebe, University of Calgary

Medical vs Electrical Therapy for Temporal Lobe Epilepsy

The primary goal is to determine whether hippocampal electrical stimulation (HS) is safe and more effective than simply implanting an electrode in the hippocampus without electrical stimulation (HI), in patients with mesial temporal lobe epilepsy (MTLE). This will be assessed by the rate of complex partial seizures per person-month over 6 months of follow-up in HS vs. HI. There are two treatment arms: 1) Hippocampal Electrode Implantation with Stimulation (HS). 2) Hippocampal Electrode Implantation without stimulation (HI). The investigators expect to demonstrate that HS is safe and superior to HI in controlling seizures in patients with MTLE.

Study Overview

Status

Terminated

Detailed Description

This is a multicentre, parallel-group, double blind randomized controlled trial involving patients with MTLE who may be candidates for resective surgery or whose memory function precludes resective surgery. Eligible patients will be randomized in a 2:1 ratio into hippocampal electrode implantation with stimulation (HS), or hippocampal electrode implantation without stimulation (HI). Patients will be followed for seven months after randomization. One month will be devoted to adjustment of interventions, and 6 months to follow-up and outcome assessment. At the end of seven months, all patients will be offered the option of HS, electrode removal, surgical therapy or medical therapy, based on best evidence and patient preference.

Primary Question: In patients with MTLE, over a 6-month period:

Is continuous HS plus medical therapy (MT) more efficacious than hippocampal implantation (HI) plus MT in reducing seizure frequency?

Secondary Questions: In patients with MTLE, over a 6-month period:

  1. Is HS safe?
  2. What is the effect of HS on cognition, mood, and quality of life?
  3. What is the effect of HS on psychiatric morbidity?
  4. Is the efficacy of HS associated with the presence, location and amount of interictal hippocampal spikes on depth electrode recordings?

Study Type

Interventional

Enrollment (Actual)

8

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Alberta
      • Calgary, Alberta, Canada
        • Foothills Medical Centre, Clinical Neurosciences

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Unilateral or Bilateral Mesial Temporal lobe Epilepsy.
  • Age ≥ 18 years.
  • Global IQ ≥70.
  • Failure of ≥ 2 AEDs approved for treatment of partial seizures, used alone or in combination at recommended dosages.
  • Average ≥ 3 seizure-days per month in prior 6 months during which disabling seizures occurred. Disabling seizures are defined as complex partial seizures with or without secondary generalization, or as simple partial seizures that are noticeable by others or interfere with function.
  • Ability to complete self-administered questionnaires.
  • Availability of reliable collateral historian or witness.
  • Patient preference for non-resective surgery, or not a candidate for mesial temporal resection.
  • Give written informed consent.

Exclusion Criteria:

  • Extratemporal or multifocal epilepsy.
  • MRI evidence of potentially epileptogenic lesions outside the mesial temporal region.
  • Lesions precluding electrode implantation (eg, vascular malformations, vascular tumors).
  • Severe hippocampal sclerosis that in the surgeon's opinion precludes accurate electrode placement.
  • Brain lesions that demand prompt surgical therapy (eg, malignant tumors, vascular malformations).
  • Progressive neurological disorders (eg, malignant tumor, dementia, degenerative disorders).
  • Medical or psychiatric conditions precluding surgery or interfering with adherence to treatment and follow-up.
  • Planned pregnancy during the study. Women of child-bearing age will require a negative pregnancy test and adequate contraception methods.
  • Ongoing or planned participation in other studies of new epilepsy therapies.
  • Contraindication for stereotactic surgery, e.g. bleeding diathesis, anticoagulants, treatment with valproate at the time of surgery (risk of bleeding).
  • Any condition that would make participation in the trial detrimental to the patient's health.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: QUADRUPLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Hippocampal Stimulation
Hippocampal Stimulation (Stimulator is turned ON) Surgical Intervention
Surgical Implantation of electrode and stimulator
SHAM_COMPARATOR: Hippocampal Implantation
Hippocampal Implantation (Stimulator is turned OFF)Surgical Intervention
Surgical Implantation of electrode and stimulator

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Rate of complex partial seizures (with or without secondary generalization) per person-month over 6 months of follow-up.
Time Frame: Months 1-7
Months 1-7

Secondary Outcome Measures

Outcome Measure
Time Frame
Cognitive function: Change in mean scores from baseline to end of study.
Time Frame: Months 1-7
Months 1-7

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Samuel Wiebe, MD, University of Calgary

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2008

Primary Completion (ACTUAL)

March 1, 2012

Study Completion (ACTUAL)

March 1, 2012

Study Registration Dates

First Submitted

July 15, 2008

First Submitted That Met QC Criteria

July 15, 2008

First Posted (ESTIMATE)

July 17, 2008

Study Record Updates

Last Update Posted (ESTIMATE)

April 2, 2012

Last Update Submitted That Met QC Criteria

March 28, 2012

Last Verified

March 1, 2012

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Temporal Lobe Epilepsy

Clinical Trials on Hippocampal Electrical Stimulation

Subscribe